Phase 3 A.R.R.O.W. Study Of Once-Weekly KYPROLIS® (Carfilzomib) Regimen Meets Primary Endpoint Of Progression-Free Survival In Relapsed And Refractory Multiple Myeloma Patients
Go back to Phase 3 A.R.R.O.W. Study Of Once-Weekly KYPROLIS® (Carfilzomib) Regimen Meets Primary Endpoint Of Progression-Free Survival In Relapsed And Refractory Multiple Myeloma Patients| Amgen Inc (NASDAQ: AMGN) | Delayed: 392.77 +7.12 (1.85%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $385.65 | 52 Week High | $176.85 | |||
| Open | $385.71 | 52 Week Low | $133.64 | |||
| Day High | $394.50 | P/E | 59.15 | |||
| Day Low | $381.90 | EPS | $6.64 | |||
| Volume | 1,257,243 | |||||
